Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
[PDF][PDF] Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
W Doehner, SD Anker, J Butler, F Zannad, G Filippatos… - 2022 - researchgate.net
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
W Doehner, SD Anker, J Butler… - European heart …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
W Doehner, SD Anker, J Butler, F Zannad… - European Heart …, 2022 - europepmc.org
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
W Doehner, SD Anker, J Butler… - European Heart …, 2022 - researchonline.lshtm.ac.uk
BACKGROUND: The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the
risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
W Doehner, SD Anker, J Butler… - European Heart …, 2022 - search.ebscohost.com
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
[HTML][HTML] Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
W Doehner, SD Anker, J Butler, F Zannad… - European Heart …, 2022 - ncbi.nlm.nih.gov
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
[PDF][PDF] Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
W Doehner, SD Anker, J Butler, F Zannad… - European Heart …, 2022 - academic.oup.com
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
W Doehner, SD Anker, J Butler, F Zannad… - European Heart …, 2022 - hal.science
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
W Doehner, SD Anker, J Butler, F Zannad… - European Heart …, 2022 - hal.univ-lorraine.fr
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …